Two recent studies have provided conflicting evidence about the association between the gene encoding serpin peptidase inhibitor, clade G, member 1 (SERPING1) and age-related macular degeneration (AMD). An article in The Lancet [1] suggested that a variant (rs2511989) in intron 6 of SERPING1 conferred protection against the development of AMD in case-control studies from the UK and USA. A follow-up study [2] showed the absence of any association in two US case-control studies, including the AREDS cohort [3] . As a member of the classical complement pathway, SERPING1 is a plausible candidate gene for AMD since several genes encoding proteins involved in the innate immune response (CFH [4] [5] [6] [7] , C2/CFB [8] , C3 [9, 10] ), are robustly associated with the development of this disorder. To test this hypothesis further, we genotyped rs2511989 in seven large case-control studies involving individuals of European descent (4881 patients with AMD and 2842 matched controls).
Samples from all cohorts in the seven centers were collected and genotyped independently to minimize data selection, analysis, or interpretation bias. Data from the seven studies are summarized in Table 1 and Figure 1 . They show, both independently and collectively, that there is no significant association between the rs2511989 variant in the SERPING1 gene and AMD. In fact, data from no single study suggested even a trend towards protective association (p>0·3 in all cohorts; Table 1 ); one cohort (AREDS) suggested an opposite, marginally significant (p=0·03), trend towards increased susceptibility. However, the study by Park and colleagues [2] found no association after genotyping more AREDS samples, thereby suggesting that the marginal association detected in our study is due to a limited sample size. The minor allele frequency (MAF) for the rs2511989 single nucleotide polymorphism (SNP) varied substantially between studies, from 0·35 and 0·45 both in AMD patients (average 0·40) and in controls matched for age and ethnic group (average 0·40). However, there was almost no difference in the MAF between patients and controls within all, except for the AREDS, studies. When summarizing the data across cohorts, the MAF of the rs2511989 SNP was practically identical in 2842 controls and in 4881 patients with AMD (0·40), clearly showing no association (p=0·99; odds ratio 1, Table 1 ). The same lack of significance was seen for all AMD subphenotypes, early AMD, geographic atrophy, and choroidal neovascularization, when analyzed separately. Since the other SNPs (eg, rs2509879, rs2511988, etc) reported in the study by Ennis and colleagues are in high linkage disequilibrium with the rs2511989 variant [1] , the MAFs for those confirmed the rs2511989 data (not shown) [2] , as did a combined analysis of all three studies by the Mantel-Haenszel fixed effects model (Figure 1) . Excluding experimental errors discussed by Park and colleagues [2] , the difference between our collective findings and those published by Ennis and colleagues could be explained by the two following scenarios:
(1) Whereas most methods used in our study closely match those used by Ennis and colleagues (genotyping methods, selection criteria for AMD patients, etc), the selection and matching of controls in the seven centers in this study were more rigorous by age and, in some centers (Germany, the Netherlands), also by ethnicity. The significantly higher MAFs in controls in both cohorts used in Ennis and colleagues' study (average 0·46 vs. 0·40 in this study and the one by Park and colleagues [2] , p=8×10 −6 ) could be explained by the fact that controls were younger than AMD patients [1] .
(2) Other possible sources for the difference in results could be non-random sampling of study populations or population substructure (stratification). For example, although there was no significant difference in MAFs between any of the AMD and control cohorts within any one study, the same numbers varied significantly between some studies (MAF 0·35 in AMD cases from New York vs. >0·41 in all other cohorts), probably originating from varied ethnic composition within populations of European descent. The New York (Columbia University) study population originates mainly from eastern Europe, whereas that from Iowa from western Europe and ), suggesting that calculation of a combined odds ratio is not valid.
Scandinavia. At the same time it is of interest that one of the two cohorts in Ennis and colleagues' study (248 AMD cases) was collected at exactly the same location, the University of Iowa, as was one of the seven cohorts in our study (368 AMD cases). However, whereas the frequencies of the minor allele in Iowa controls were very similar in the two studies (0·44 vs. 0·42), they differed significantly in patients with AMD (0·35 vs. 0·44; p=0·001).
In summary, analysis of the rs2511989 variant in SERPING1 in seven large, well characterised case-control studies did not confirm an association between this variant and AMD. Since there is also no evidence of a functional role for this variant, it is unlikely that the SERPING1 gene has a significant, if any, role in the etiology of AMD. Table 2 C= controls; N= number of subjects; AMD= age-related macular degeneration.
Materials and Methods

Study Cohorts
The consortium includes seven international cohorts of patients diagnosed with AMD and controls matched by age and ethnicity, all of whom have been extensively characterized and described in previous genetic and epidemiological studies of AMD as follows: from Columbia University, New York, USA [5, 8, 11] ; University of Iowa, Iowa City, USA [5, 8] 
Grading
All study subjects underwent clinical examination and stereoscopic color fundus photography after pharmacologic mydriasis, and were graded according to the International Classification and Grading System for AMD [19] (Melbourne and Würzburg sites), the Rotterdam modification of the International classification [14, 20] (Columbia, Iowa, Amsterdam and Rotterdam sites), or the classification established by the AREDS study [3] (for the AREDS study). The detailed description of each cohort has been provided in earlier publications, as described in the previous section.
In short, AMD patients were subdivided into phenotypic categories: early AMD (eAMD), geographic atrophy (GA) and choroidal neovascularization (CNV) AMD based on the classification of their most severe eye at the time of their entry into the study. The average age of subjects was ~75 years in all cohorts (Tables 2 and 3 ).
Subjects were graded as 'unaffected controls' only when fundus photographs showed no signs of AMD; i.e., they had clear fundi at >60 years of age or <5 small 
Statistical analysis
Genotypes were tabulated in Microsoft Excel and presented to SPSS for contingency table analysis as described previously [5, 8] . Allele tests were performed with Chisquare analysis and the G-test was used to assess genotype distributions. Compliance to Hardy-Weinberg equilibrium was checked using SAS/Genetics (SAS Institute), and all cohorts in both cases and controls survived a cutoff of p>0.05. The combined analysis of all three studies (Ennis et al., Park et al., and ours) was performed using R statistical package. The Mantel-Haenszel fixed effects model was used to estimate individual odds ratios, summary of pooled effect, and test for heterogeneity.
